IP Library Patent Application 14760182
Patent Application
App. No. 14/760,182

Medium Supplements for Improved Process Performance

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/760,182
Abstract

The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate.

Claims (41)

1 . A method of producing a polypeptide of interest in a large-scale cell culture, comprising culturing mammalian cells expressing the polypeptide of interest in a cell culture medium under conditions that support expression of the polypeptide of interest, wherein said cell culture medium comprises between about 0.01 g/L and about 5 g/L dextran sulfate.

2 . A method of producing a polypeptide of interest in a large-scale cell culture, comprising

supplementing the culture with a feed medium comprising a sufficient amount of dextran sulfate to increase the dextran sulfate concentration in the culture by between about 0.01 g/L and about 5 g/L,

wherein the culture comprises cells expressing the polypeptide and a medium, and the cells are maintained under conditions that allow for expression and accumulation of the polypeptide.

3 . A method of producing a polypeptide of interest in a large-scale cell culture, comprising:

a) providing a cell culture comprising cells capable of expressing the polypeptide and a medium,

b) supplementing the culture with a feed medium comprising a sufficient amount of dextran sulfate to increase the dextran sulfate concentration in the culture by between about 0.01 g/L and about 5 g/L.

c) maintaining the cells in the dextran sulfate supplemented culture of b) under conditions that allow for expression and accumulation of the polypeptide.

4 . The method of claim 3 , wherein the medium and/or feed medium comprises ferric citrate.

5 - 9 . (canceled)

10 . The method of claim 3 , wherein the cells are maintained for between about 1 day and about 25 days.

11 - 12 . (canceled)

13 . The method of claim 3 , wherein the cells are maintained longer than cells maintained in a culture medium that is substantially free from dextran sulfate and ferric citrate.

14 - 16 . (canceled)

17 . The method of claim 3 , wherein the culture is supplemented with the feed medium between about 1 and about 25 times.

18 - 19 . (canceled)

20 . The method of claim 3 , wherein the lactate production of the cells is lower than the lactate production of cells maintained in a culture medium that is substantially free from dextran sulfate and ferric citrate.

21 - 22 . (canceled)

23 . The method of claim 3 , wherein the lactate concentration of the culture is between about 0.1 g/L and about 6 g/L.

24 - 25 . (canceled)

26 . The method of claim 3 , wherein the ammonium production of the cells is lower than the ammonium production of cells maintained in a culture medium that is substantially free from dextran sulfate and ferric citrate.

27 - 28 . (canceled)

29 . The method of claim 3 , wherein the ammonium concentration of the culture is between about 0.1 mM and about 20 mM.

30 - 31 . (canceled)

32 . The method of claim 3 , wherein the cell specific lactate production rate to the cell specific glucose uptake rate ratio (LPR/GUR ratio) of the cells is between about −0.5 and about 0.5.

33 . (canceled)

34 . The method of claim 3 , wherein the cells are CHO cells, HEK 293 cells, NSO cells, PER.C6 cells, HeLa cells, MDCK cells, or hybridoma cells.

35 - 37 . (canceled)

38 . The method of claim 3 , wherein the cells have been adapted to grow in serum free medium, animal protein free medium or chemically defined medium.

39 . The method of claim 3 , wherein the cells have been genetically modified.

40 . (canceled)

41 . The method of claim 3 , wherein the polypeptide of interest is selected from the group consisting of: an antibody, a Transforming Growth Factor (TGF) beta superfamily signaling molecule, an Fc fusion protein, and a clotting factor.

42 - 49 . (canceled)

50 . The method of claim 3 , wherein the total amount of polypeptide produced by the cells is higher than the total amount of polypeptide produced by cells maintained in a culture medium that is substantially free from dextran sulfate and ferric citrate.

51 . (canceled)

52 . The method of claim 3 , wherein the specific productivity of the cells is higher than the specific productivity of cells maintained in a culture medium that is substantially free from dextran sulfate and ferric citrate.

53 . (canceled)

54 . The method of claim 3 , wherein the culture is a perfusion culture or a fed batch culture.

55 - 56 . (canceled)

57 . The method of claim 3 , wherein the medium is a serum free medium, animal protein free medium or a chemically defined medium.

58 - 65 . (canceled)

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2019
From: GLORIANA THERAPEUTICS SARL
To: GLORIANA THERAPEUTICS, INC.
Reel/Frame 049005/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: BIOGEN MA INC.
To: GLORIANA THERAPEUTICS SARL
Reel/Frame 041887/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2015
From: GILBERT, ALAN; MCELEARNEY, KYLE; DOBROWSKY, TERRENCE MICHAEL; KSHIRSAGAR, RASHMI ROHIT
To: BIOGEN MA INC.
Reel/Frame 037006/0839 →